Hybrid eventDay 1 In-personDay 2 Virtual

International Depression Research & Therapeutics Summit

Advances in Treatment-Resistant Depression

May 26–27, 2027 New York, USA · Venue to be announced
Submit abstractRegister as delegate

DatesMay 26–27, 2027Two days

LocationNew York, USAVenue to be announced

May 26In-personFull scientific programme

May 27VirtualOnline programme

About the summit

Keynote talks, four panels, oral presentations and posters. A focused scientific exchange on treatment-resistant depression.

The summit brings together researchers, psychiatrists, clinical investigators and industry research teams. Discussions examine study populations, prior treatment exposure, methods and limitations, with the aim of identifying research priorities and evidence gaps.

Neural network brain
Selecting treatment after inadequate response
Maintaining improvement over time
Refining neuromodulation strategies
Measuring outcomes that matter to patients

Co-located with

SentCroft US Edition · New York · May 2027

Organised by MedGlobal Connect
Who should attend

Built for people who work on depression

People who conduct depression research, develop treatments, run clinical trials, or make decisions about specialist services.

Academic and clinical investigators

Professors of Psychiatry, Principal Investigators, Directors of Depression Research

Specialist clinicians

Mood Disorder Psychiatrists, Interventional Psychiatrists, TMS and ECT Service Directors

Pharmaceutical and biotechnology teams

Heads of CNS Research, Clinical Development Directors, Translational Medicine Leads, Medical Affairs

Neuromodulation and research technology

Clinical Research Directors, Medical Directors, Scientific Affairs Leads

Clinical research organisations

CNS Therapeutic Leads, Trial Operations Directors, Site Network Directors

Research methods specialists

Biostatisticians, Psychometricians, Imaging Scientists, Clinical Outcome Assessment Specialists

Emerging researchers

Psychiatry Fellows, Postdoctoral Researchers, Doctoral Candidates

Patient research partners

Experienced patient advisers involved in study design

Scientific programme

Four scientific sessions

Each session has one panel discussion followed by selected oral presentations. These are also the abstract submission topics.

Session 1

Predicting Treatment Response in Depression

Can clinical characteristics and biological measures help identify which treatment is most likely to benefit an individual patient?

  • EEG and neuroimaging predictors of antidepressant response
  • Anhedonia, cognitive impairment and other patient subgroups
  • Inflammatory and metabolic markers of treatment outcome
  • Clinical predictors of non-response and relapse
  • Validation of prediction models in independent populations
  • Prospective studies of biomarker-guided treatment selection
Panel discussionCan biomarkers improve treatment selection in depression?
Session 2

New Antidepressant Treatments and Maintenance Strategies

Research on novel treatments, and the practical question of maintaining benefit after an initial response.

  • Rapid-acting antidepressants and their mechanisms
  • Ketamine and esketamine outcomes, tolerability and maintenance
  • Novel pharmacological targets in major depressive disorder
  • Investigational psychedelic treatments and trial methodology
  • Treatment continuation, discontinuation and relapse
  • Comparative and combination treatment studies
Panel discussionMaintaining response after rapid-acting treatment
Session 3

Neuromodulation for Treatment-Resistant Depression

Stimulation methods, patient selection, treatment delivery and longer-term outcomes.

  • Repetitive TMS and theta-burst stimulation
  • Accelerated treatment schedules
  • Personalised and imaging-guided stimulation targets
  • ECT outcomes, cognitive effects and continuation treatment
  • Predictors of response and durability after neuromodulation
  • Emerging approaches, with investigational status clearly stated
Panel discussionChoosing the patient, protocol and maintenance approach
Session 4

Better Depression Trials and Meaningful Recovery

Why studies can be hard to interpret, and how future trials can produce more useful findings.

  • Defining treatment resistance and prior treatment adequacy
  • Patient selection, recruitment and representative populations
  • Placebo response, masking and rater reliability
  • Remission, functioning, cognition and quality of life
  • Long-term follow-up, missing data and discontinuation
  • Pragmatic trials, comparative effectiveness and sequencing
Panel discussionWhat should a depression trial measure beyond symptom improvement?
Submit your research

Present your work in New York.

Abstracts are welcome across all four scientific sessions. Selected work is presented as oral talks or at the moderated poster session.

Oral presentationAfter each panel
Poster presentationModerated poster session
Submit abstractRegister as speaker

Abstract topics

1Predicting Treatment Response in Depression
2New Antidepressant Treatments and Maintenance Strategies
3Neuromodulation for Treatment-Resistant Depression
4Better Depression Trials and Meaningful Recovery
Agenda

Day 1 programme

May 26, 2027 · In-person · New York. Timings are in local time.

Registration and refreshments
Welcome from the Scientific Chair
Opening Keynote: Treatment-Resistant Depression: Where the Evidence Is Changing Practice
Session 1 · Predicting Treatment Response in Depression
Panel 1: Can biomarkers improve treatment selection in depression?
Oral presentations: Biomarkers and predictors of treatment response
Refreshment break and exhibition
Session 2 · New Antidepressant Treatments and Maintenance Strategies
Panel 2: Maintaining response after rapid-acting treatment
Oral presentations: Novel treatments and longer-term outcomes
Lunch and exhibition
Moderated posters: Research across the four scientific sessions
Session 3 · Neuromodulation for Treatment-Resistant Depression
Panel 3: Choosing the patient, protocol and maintenance approach
Oral presentations: Neuromodulation and treatment outcomes
Refreshment break and exhibition
Session 4 · Better Depression Trials and Meaningful Recovery
Panel 4: What should a depression trial measure beyond symptom improvement?
Oral presentations: Trial methods, functioning and relapse prevention
Closing acknowledgements

Day 2 · May 27, 2027 · Virtual programme

A virtual research programme for delegates joining online. The detailed schedule will be announced on this page.

Partner with the summit

Meet the people shaping depression research

Opportunities are matched to the audience you want to reach. Contact us to discuss what suits your goals.

Pharmaceutical and biotechnology companies

You will meet

Depression investigators, clinical development leaders, trial sites

How to take part

Principal sponsorship, exhibition, and mutually agreed investigator meetings

Neuromodulation companies

You will meet

Interventional psychiatrists, service directors, researchers

How to take part

Exhibition and scientific engagement around Session 3

Biomarker and research technology providers

You will meet

Translational researchers, imaging scientists, study leaders

How to take part

Exhibition linked to Session 1 and poster research

CROs and trial service providers

You will meet

Biotech development teams, principal investigators, site directors

How to take part

Exhibition and research partnership meetings

Outcome assessment and trial data providers

You will meet

Trial methodologists, clinical operations teams, investigators

How to take part

Exhibition linked to Session 4

Discuss a partnership

No pricing is shown online. Tell us who you want to meet and we will propose the right fit.

Partnership enquiry
Attend the summit

Join us in New York.

Apply as a delegate, register as a speaker or submit an abstract. Co-located with SentCroft US Edition.

Register as delegateRegister as speakerSubmit abstract
Day 1 · May 26In-person
Day 2 · May 27Virtual
CityNew York, USA
VenueTo be announced